Chinese generic company takes another step along the road to becoming a full-blown originator
China’s Shanghai Fosun Pharmaceutical has announced a cooperation agreement with Switzerland-based biopharmaceutical and research company Sellas Life Sciences Group for the licensing of $533 million worth of IP rights relating to diabetes and cancer…
To read more
Register for limited access
Register to receive our weekly newsletter and access two of our subscriber-only articles per month.
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.